Full Press Release Details
Regeneron Receives Complete Response Letter From FDA for ARCALYST® (rilonacept) sBLA for the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapies.
REGN
Regeneron Receives Complete Response Letter From FDA for ARCALYST® (rilonacept) sBLA for the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapies
Key Takeaway: Regeneron Receives Complete Response Letter From FDA for ARCALYST® (rilonacept) sBLA for the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapies